Results 31 to 40 of about 6,178 (191)

Renally Generated Ammonia as a Cause of Hyperammonaemic Non-Hepatic Encephalopathy. [PDF]

Nephrology (Carlton)
ABSTRACT Encephalopathy with high ammonia levels is most commonly associated with cirrhosis or urea cycle disorders, but it can also result from renal ammoniagenesis when renal excretion of ammonium is impaired. In the literature, this has been shown to occur in the presence of (1) urinary diversion to a segment of intestine; (2) urea‐splitting ...
Nkunu VE, Mak KYL, Dodia K, Morales FD, Chan AKJ, Alexander RT, Hwang PM.   +6 more
europepmc   +2 more sources

Complex interaction of deferasirox and Pythium insidiosum: iron-dependent attenuation of growth in vitro and immunotherapy-like enhancement of immune responses in vivo. [PDF]

PLoS ONE, 2015
Pythium insidiosum iron acquisition mechanisms are unknown. We previously showed that the iron chelator deferasirox had weak activity in vitro and in rabbits with experimental pythiosis. Here we show that deferasirox causes damage to P. insidiosum hyphae
Régis A Zanette, Paula E R Bitencourt, Dimitrios P Kontoyiannis, Rafael A Fighera, Mariana M Flores, Glaucia D Kommers, Priscila S Silva, Aline Ludwig, Maria B Moretto, Sydney H Alves, Janio M Santurio   +10 more
doaj   +1 more source

Impact of iron chelation with deferasirox on telomere length and oxidative stress in hemodialysis patients: A randomized study

Nefrología (English Edition)
Background: Recent studies have demonstrated the effectiveness, safety, and tolerability of deferasirox in patients in peritoneal dialysis, however, its effect has not been studied in patients undergoing hemodialysis. Objective: To investigate the impact
Blanca Olivia Murillo Ortiz, Joel Ramírez Emiliano, Marcos Javier Romero Vázquez, Lauro Fabián Amador Medina, Sandra Martínez Garza, Edna Montserrat Ramos Rodríguez   +5 more
doaj   +3 more sources

Synthesis and Characterization of Deferasirox PLGA Nanoparticles and Investigation of Toxicity in Cell Model

Journal of Mazandaran University of Medical Sciences, 2022
Background and purpose: Cancer is one of the causes of mortality worldwide. Evidence suggests that iron depletion by a chelator agent suppresses the development of some cancer cells. Deferasirox is shown to have anticancer properties.
Hamidreza Mohammadi, Javad Akhtari, Sara Assadpour, Mitra Kamali, Pedram Ebrahimnejad   +4 more
doaj  

The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases [PDF]

, 2019
\ua9 2019 American Chemical Society.Fe(II)- and 2-oxoglutarate (2OG)-dependent JumonjiC domain-containing histone demethylases (JmjC KDMs) are "epigenetic eraser" enzymes involved in the regulation of gene expression and are emerging drug targets in ...
Abboud MI, Tzu-lan, Yeh, Yeh T-L, Martin, Roatsch, Akane, Kawamura, Wenzler S, Dina, Robaa, Wilkins SE, Manfred, Jung, Roatsch M, Martine I., Abboud, Isabelle, Moneke, Ahrens TD, Schule R, Wolfgang, Sippl, Rebecca L., Hancock, Robaa D, Schleicher E, Kerstin, Lippl, Erik, Schleicher, Sippl W, Hancock RL, Serrer K, Sarah E., Wilkins, Lassmann S, Barthes NPF, Kerstin, Serrer, Diederichs S, Kuo-Feng, Hsu, Sandra, Wenzler, Silke, Lassmann, Tarhonskaya H, Theresa D., Ahrens, Hanna, Tarhonskaya, Franz H, Inga, Hoffmann, Schofield CJ, Hsu K-F, Sven, Diederichs, Henriette, Franz, Hoffmann I, Moneke I, Kawamura A, Roland, Schüle, Jung M, Christopher J., Schofield, Lippl K   +46 more
core   +2 more sources

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

Haematologica, 2011
Background Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and ...
Alessia Pepe, Antonella Meloni, Marcello Capra, Paolo Cianciulli, Luciano Prossomariti, Cristina Malaventura, Maria Caterina Putti, Alma Lippi, Maria Antonietta Romeo, Maria Grazia Bisconte, Aldo Filosa, Vincenzo Caruso, Antonella Quarta, Lorella Pitrolo, Massimiliano Missere, Massimo Midiri, Giuseppe Rossi, Vincenzo Positano, Massimo Lombardi, Aurelio Maggio   +19 more
doaj   +1 more source

Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes [version 2; peer review: 2 approved]

F1000Research, 2023
Background Excess iron deriving from a chronic transfusion and dietary intake increases the risk for cardiac complications in β-thalassemia major patients.
Khairunnisa Khairunnisa, Heru Noviat Herdata, Eka Destianti Edward, Sulaiman Yusuf   +3 more
doaj   +1 more source

Genetic polymorphisms influencing deferasirox pharmacokinetics, efficacy, and adverse drug reactions: a systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Objective: Deferasirox is an iron-chelating agent prescribed to patients with iron overload. Due to the interindividual variability of deferasirox responses reported in various populations, this study aims to determine the genetic polymorphisms that ...
Kittika Yampayon, Puree Anantachoti, Bunchai Chongmelaxme, Varalee Yodsurang, Varalee Yodsurang   +4 more
doaj   +1 more source

Desensibilización a deferasirox en una paciente con hemocromatosis. Reporte de un caso

Revista Alergia México, 2023
Antecedentes: Deferasirox es un quelante de hierro activo, indicado en el tratamiento de pacientes con hemocromatosis; sin embargo, se ha informado que el 28% de los casos puede tener reacciones adversas al fármaco. El protocolo de desensibilización para
Nadia Karina Aguilar Hinojosa, Evelyn Itzamara Figueroa Saavedra   +1 more
doaj   +1 more source

Acute kidney injury due to thin basement membrane disease mimicking Deferasirox nephrotoxicity: a case report

BMC Nephrology, 2018
Background Although the renal toxicity of Deferasirox, an oral iron chelator, has been reported to be mild, there have been reports of acute interstitial nephritis or Fanconi syndrome due to this agent.
Keiko Oda, Kan Katayama, Akiko Tanoue, Tomohiro Murata, Yumi Hirota, Shoko Mizoguchi, Yosuke Hirabayashi, Takayasu Ito, Eiji Ishikawa, Kaoru Dohi, Masaaki Ito   +10 more
doaj   +1 more source